<DOC>
	<DOCNO>NCT01711593</DOCNO>
	<brief_summary>Despite advance medication , allergic disease , include allergic asthma continue rise prevalence . For reason , need good understand mechanisms allergic disease novel insight modulate allergic inflammation . The investigator hypothesize much remains learn behavior T effector T regulatory cell allergic disease . Furthermore , investigator hypothesize novel mechanism allergic tolerance may exist , elucidation mechanism may provide insight novel therapeutic strategy control allergic disease . The investigator investigate capacity T cell tolerance induction allergic subject novel type immune tolerizing dendritic cell ( it-DC ) . The investigator assess whether vitro generate it-DCs capacity induce antigen-specific T regulatory cell suppress allergen-specific T effector cell function vitro . Standardized Cat Allergen extract Dust Mite Allergens use generate change airways occur exposure allergen . For investigation , route administration topical application titrate allergen bronchoscopically isolated subsegment one lobe one lung . The dose biologic determine prior skin-prick testing .</brief_summary>
	<brief_title>Induced Tolerogenic Dendritic Cells Modulators Allergic Asthma</brief_title>
	<detailed_description>This single-center , open-label , control mechanistic study before-and-after allergen instillation study use subject his/her control . Reliability study measurement expression accomplish compare repeat measurement . Additional control provide measure expression marker know stable expression , include cell structural protein chemokine marker investigator know induced experimental paradigm previous study . This investigational study . Subjects receive investigational product , either Standardized Cat Allergen Extract Standardized Dust Mite Allergen ( Dermatophagoides farinae D. pteronyssinus ) . No subject give placebo . There 2 cohort , allergic asthmatic ( AA ) healthy control ( HC ) . The main comparison measurement primary secondary outcome measure : ( 1 ) diluent versus allergen-challenged segment lung asthmatic subject ( 2 ) comparison responses allergic asthmatic ( AA ) healthy control ( HC ) . The investigator enroll 20 AA subject ( 10 Track 1 &amp; 10 Track 2 ) 10 HC subject ( Track 1 ) . There randomization . The choice allergen determine allergy skin testing . When subject allergic cat dust mite , one select goal representative sample cat dust mite challenge cohort . The 10 allergic asthmatic ( AA ) subject HC subject Track 1 undergo preliminary screening test provide 200 ml blood DC T cell study one occasion . Track 1 subject undergo bronchoscopy , bronchoalveolar lavage , segmental allergen challenge . The 10 allergic asthmatic ( AA ) subject Track 2 undergo SAC either standardized cat mite allergen . These subject also donate 200 ml blood two occasion separate minimum 4 week 12 week .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Subjects Allergic Asthma ( AA subject ) : 1 . All subject baseline FEV1 le 75 % predict value bronchodilator administration . 2 . All subject clinical history allergic symptom cat dust mite allergen positive allergen prick test ( 3 mm diameter great diluent control ) 3 . Lifelong absence cigarette smoking ( lifetime total &lt; 5 packyears none 5 year ) . 4 . Willing able give inform consent . 5 . Expressed desire participate interview principal investigator . 6 . Age 18 50 year . 7 . A methacholine PC20 &lt; 16 mg/ml . 8 . Asthma severity define : require step 3 therapy ( NHLBI Guidelines , 2007 ) , wellcontrolled validated asthma control test ( ACT ) score &gt; 19 one month prior screen visit , able tolerate 2 week stoppage inhale corticosteroid prior Visit 2 . Healthy Control Subjects ( HC subject ) : Normal control subject individual good overall health , age sex match asthmatic group , age 18 50 nonallergic , i.e . entirely negative panel prick skin test history allergic rhinitis asthma , history allergic symptom cause cat dust mite allergen exposure , lifelong nonsmoker cigarette ( define lifetime total less 5 packyears none 5 year ) , normal spirometry ( i.e . FEV1 FVC least 90 % predict ) methacholine PC20 &gt; 16 mg/ml . Subjects Allergic Asthma ( AA subject ) : 1 . Women childbearing potential pregnant ( base urine betaHCG test ) , sexually active use contraception , seek become pregnant , nursing . 2 . The presence spontaneous asthmatic episode clinical evidence upper respiratory tract infection within previous 6 week . 3 . Participation research study involve drug biologic 30 day prior study . 4 . Intolerance albuterol , atropine , lidocaine , fentanyl , midazolam . 5 . Antihistamines within 7 day screen visit . 6 . Presence diabetes mellitus , congestive heart failure , ventricular arrhythmia , history cerebrovascular accident , renal failure , history anaphylaxis , cirrhosis . 7 . Use systemic steroid , increase use inhaled steroid , beta blocker MAO inhibitor visit asthma exacerbation within 1 month screen visit . 8 . Antibiotic use respiratory disease within 1 month characterization visit respiratory tract infection within 6 week bronchoscopy visit . 9 . A history asthmarelated respiratory failure require intubation . 10 . Quantitative skinprick test positive reaction allergen concentration 0.056 BAU AU/ml . 11 . Subjects high possibility poor compliance study . 12 . Have history cigarette smoking within past 5 year &gt; 5 pack year total . 13 . Having secondhand cigarette smoke exposure indoor furry pet except case dog , subject allergic dog subject negative skin test dog . 14 . Other lung disease , sarcoidosis , bronchiectasis active lung infection . 15 . Use Xolair ( omalizumab antiIgE monoclonal antibody ) 6 month . 16 . Immunotherapy cat dust mite extract past . 17 . Use prophylactic aspirin cardiovascular disease . 18 . NonEnglish speaker . 19 . Weight le 110 pound 20 . Hematocrit &lt; 0.36 female , &lt; 0.38 male . Healthy Normal Control Subjects ( HC subject ) : 1 . A history allergy , asthma , nasal sinus disease . 2 . Exclusion criterion # 1 , 38 1020 ( A . ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Allergic</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Airway</keyword>
	<keyword>Challenge</keyword>
	<keyword>Chemokines</keyword>
	<keyword>Tolerization</keyword>
</DOC>